The FDA record for K254090 lists Hologic, Inc. at 600 Technology Dr., Newark, DE, as applicant for I-View®, with Manuela Restrepo Parra identified as senior regulatory affairs specialist in the agency's clearance letter. The submission was received December 19, 2025, and decided September 2, 2026, as substantially equivalent under a traditional pathway with a summary. The record places the device in Class II, regulation 21 CFR 892.1715, product code MUE, radiology advisory committee. The linked collection for this profile holds one 510(k) record, decided SESE; that count describes the retrieved filings, not company-wide totals. [1][2]
The applicant and the cleared device identity
K254090 names Hologic, Inc. as applicant and I-View® as the trade/device name, with the device described as a full-field digital mammography system. The FDA letter repeats the regulation number and name, the Class II designation and product code MUE, and records the submission as dated December 16, 2025 and received December 19, 2025. The decision code is SESE, described as substantially equivalent, and the record notes a summary rather than a statement. [1][2]
The openFDA fields attached to the same record associate the product code with the device name Full Field Digital, System, X-Ray, Mammographic, device class 2, regulation number 892.1715 and medical specialty radiology. Those fields describe the regulatory classification of the cleared device; they do not establish commercial availability, installed base or clinical performance. [1]
Documented components and platform references
The FDA letter references the Envision Mammography Platform and Selenia Dimensions FFDM, noting that the Envision platform was approved via P080003/S009 and supports I-View requirements, with no impact to safety and effectiveness stated in the reviewed text. The same document describes display of low energy and subtracted images for clinical use and mentions introduction of an estimation algorithm. These are descriptions of submitted content, not independent findings of this profile. [2]
Hologic's product page identifies I-View® 2.0 Contrast-Enhanced Mammography Software and describes acquisition of paired high- and low-energy images in rapid succession. The page also lists documents including a specification sheet, a Hologic x Bayer contrast-enhanced mammography brochure, a program-growth item, reimbursement material, sales terms, safety data sheets and package inserts. Those listings are publisher statements about available documentation. [3]
Biopsy-related software described by the manufacturer
A Hologic white paper by Andrew Smith, identified as Vice President Breast Health R&D, discusses methods I-View software users may consider when performing biopsy of lesions seen in contrast images that cannot be biopsied by an alternative method based on second-look ultrasound. The paper is a manufacturer publication; it is not an FDA clearance document and does not establish outcomes. [6]
A Hologic brochure describes Affirm Contrast Biopsy software in combination with I-View Contrast-Enhanced Mammography technology and the Affirm Upright Breast Biopsy Guidance System as a complete contrast biopsy solution, and describes I-View 3-in-1 Contrast-Enhanced Imaging software for 2D, contrast-enhanced and tomosynthesis images under one compression. A separate Hologic brochure, I-View CEM and Affirm CEBx, notes that CEM and the Affirm system must be on the same gantry. These are manufacturer descriptions of product configuration. [7][4]
Filing scope and what the record does not show
The retrieved collection contains one 510(k) record, and the smaller record sample contains the same single entry, K254090, decided SESE. Both counts describe the retrieved filings as of the snapshot date; neither is a measure of total company submissions, sales, portfolio breadth or safety performance. No premarket approval, supplement or recall record appears in the retrieved material for this profile. [1]
Hologic and Bayer are described in a Hologic brochure as partnering to provide a coordinated contrast-enhanced mammography solution, with statements about installation, training and service coordination. The brochure also lists additional equipment such as a power injection system and a mammography positioning chair, and states that patients can have adverse reactions to contrast agents, referring readers to full prescribing information. Ownership, headquarters and commercial terms beyond these publisher statements are not established by the retrieved records. [5]







